ClinicalTrials.gg
CompletedNCT06719882Updated Oct 6, 2026

Vivity Study in Taiwan

An observational study in Cataract, sponsored by Taipei Nobel Eye Clinic. Completed at 1 site in Taiwan. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Taipei Nobel Eye Clinic · Observational

How we know

Updated Oct 6, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
90
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Cataract with a site in Taiwan — 2 open to participants now, 2 under way, none of them phase 3. Cataract · Taiwan.

Started
2022
with 2 others
Observational
6 of 15
none open now
Registered
11th of 15
by date
Lead sponsor
2 of 15
Taipei Nobel Eye Clinic

Among the 15 studies in Cataract with a site in Taiwan, this one is one of 3 that started in 2022, is one of 6 observational ones, and was the 11th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

2 of the 15 studies in Cataract with a site in Taiwan are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Cataract with a site in Taiwan, or all of them as a file.
02

Study summary

The aim of study is to evaluate the quality of vision after bilateral Vivity or Vivity toric EDOF IOLs implantation in Taiwan.

Read the detailed description

This study was a prospective, single arm study. The inclusion criteria for this study were the presence of cataracts in both eyes and corrected distance visual acuity (CDVA) of both eyes under 20/40, who received bilateral Vivity IOL implantation after cataract surgery, targeting emmetropia or mini-monovision of both eyes. Phacoemulsification cataract surgery was performed on all patients. The exclusion criteria were complicated cataract; corneal opacities or irregularities; severe dry eye (Schirmer's test I ≤ 5 mm); amblyopia; anisometropia; surgical complications such as posterior capsular bag rupture, vitreous loss, or IOL tilt/decentration; coexisting ocular pathologies such as glaucoma, nondilating pupil, history of intraocular surgery, refractive surgery, or retinopathy; optic nerve or macular diseases; and refusal or inability to maintain follow-up. When corneal astigmatism was more than 0.75 diopters (D), a toric IOL was implanted.

03

Conditions studied

  • Cataract

Browse trials for

Keywords

  • Intraocular lens
  • Extended depth of focus
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who intended for sequential bilateral cataract surgery and implanted with Vivity/Vivity IOL would be asked to include in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with age-related cataract requiring surgery treatment
  • Patient who received bilateral, uneventful implantation of Vivity IOLs
  • Patient's IOL power is between 10-30D, and T2-T6 for toric correction
  • Cataract grade 0\~3 based on the Wisconsin cataract grading system

Exclusion criteria

  • Exclusion criteria:
  • Cataract grade 4\~5 based on the Wisconsin cataract grading system
  • Patient's IOL power is outside of 10-30D or T2-T6 for toric correction
  • Patient with the following ocular comorbidities:
  • Corneal opacities or irregularities;
  • Severe dry eye;
  • Amblyopia;
  • Glaucoma;
  • Non-dilating pupil;
  • History of intraocular surgery, laser therapy, or retinopathy;
  • Optic nerve or macular diseases;
  • Uncontrolled diabetic mellitus or systemic immune disease;
  • Refusal or unable to maintain follow-up
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
90 participants (actual)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • Vivity/Vivity toric
06

What researchers measure

Primary outcomes

  1. Visual acuity (LogMAR)

    Uncorrected binocular far, intermediate and near visual acuity. Corrected binocular far, intermediate and near visual acuity.

    Time frame: From enrollment to the end of treatment at 3 months

Other outcomes

  1. Intermediate reading speed (seconds)

    The intermediate reading speed was measured by IReST - International Reading Speed Texts Chinese Edition

    Time frame: From enrollment to the end of treatment at 3 months

07

Study locations

1 site
  • Taiwan Nobel Eye Clinic
    Taipei, Taiwan
08

References and documents

Publications

  • Kandavel R, Colvard M, Dredge J, Bayle M, Alam T, Snyder J, Hall B. Comparative Study Between Non-Diffractive Extended Depth of Focus and Monofocal Intraocular Lenses. Clin Ophthalmol. 2023 Apr 14;17:1161-1168. doi: 10.2147/OPTH.S402069. eCollection 2023. PubMed 37082300 ↗
  • Hovanesian JA, Jones M, Allen Q. The Vivity Extended Range of Vision IOL vs the PanOptix Trifocal, ReStor 2.5 Active Focus and ReStor 3.0 Multifocal Lenses: A Comparison of Patient Satisfaction, Visual Disturbances, and Spectacle Independence. Clin Ophthalmol. 2022 Jan 18;16:145-152. doi: 10.2147/OPTH.S347382. eCollection 2022. PubMed 35082481 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Oct 2024, 21 months.

Of 169 non-industry observational studies under Cataract, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 30. This study's 21 months is above that.

Counting every sponsor, half of 236 studies reached it within 16 months; a quarter within 9 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Dec 2024 → Oct 2024 and completion Dec 2024 → Nov 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2024
First posted
Dec 6, 2024
StartActual
Dec 15, 2022
Primary completionActual
Oct 7, 2024was Dec 2024
CompletionActual
Nov 5, 2024was Dec 2024
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 6, 2026
Primary completion
Dec 31, 2024→Oct 7, 2024 (actual)
Oct 6, 2026
Study completion
Dec 31, 2024→Nov 5, 2024 (actual)
Oct 6, 2026
Enrollment
100 (estimated)→90 (actual)
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Active, not recruiting→Completed
    Primary completion Dec 31, 2024→Oct 7, 2024 (now actual)
    Study completion Dec 31, 2024→Nov 5, 2024 (now actual)
    Enrollment 100 (estimated)→90 (actual)
    + 3 other changes: verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06719882
Lead sponsor
Taipei Nobel Eye Clinic
Responsible party
Chao-Kai Chang (Doctor, Taipei Nobel Eye Clinic) — Principal investigator
First posted
Dec 6, 2024
Start date
Dec 15, 2022
Primary completion
Oct 7, 2024
Completion
Nov 5, 2024
Last update
Oct 6, 2026

Study contacts

ChaoKai Chang, Ph.D.
study director · Taiwan Nobel Eye Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion